bit.bio lowers ioCells pricing and opens EU hub with next-day delivery, expanding global access to human cells for NAMs research.
19.02.2026
bit.bio secures $50 million Series C to scale human cell programming technology
bit.bio, Cambridge-based pioneer in next-generation human cell programming, has successfully closed a $50 million Series C funding...
bit.bio Publishes 2025 Sustainability Report
bit.bio, the global leader in cell programming technology, today announces the publication of its 2025 Corporate Sustainability R...
bit.bio launches Early Access programme for ioHepatocytes, a new iPSC-derived liver model
bit.bio launches Early Access for ioHepatocytes for disease and drug studies with consistent, functional human iPSC-derived hepato...
bit.bio Raises $30 Million Led by M&G Investments
Focus on Tools for the Research, Drug Discovery and Cell Therapy Markets.
bit.bio launches first-of-their-kind human iPSC-derived cells for gene activation and interference, expanding functional genomics product range
Modulate gene activity in human iPSC-derived cells with a set of CRISPR-ready tools for gene knockout, activation, and interferenc...
bit.bio Launches ioTracker Cells Range at SLAS 2025
Adding New Visualisation Functionality to Human iPSC-derived Cell Types
bit.bio Wins Landmark Patent Defence for Groundbreaking opti-ox™ Cell Programming Technology
The European Patent Office (EPO) upholds bit.bio's patent for its dual genomic safe harbour technology, opti-ox™, securing the bro...
bit.bio to Unveil iPSC Advancements and ioCells Toolkit at Society for Neuroscience 2024 Annual Conference
bit.bio's ioSensory Neurons pain research was selected for presentation at SfN’s Neuroscience 2024 press conference.